Why the study?
Percutaneous mitral valve repair requires transseptal puncture causing iatrogenic atrial septal defect, but previous data on the impact of persistent defects were diverse and inconclusive.
Does persistent iatrogenic atrial septal defect worsen clinical or echocardiographic outcomes in patients who underwent percutaneous mitral valve repair?
Does persistent iatrogenic atrial septal defect worsen clinical or echocardiographic outcomes in patients who underwent percutaneous mitral valve repair?
Persistent iatrogenic atrial septal defect after percutaneous mitral valve repair is common (62%) and associated with increased right ventricular diameter, but does not significantly impact 2-year mortality or rehospitalization rates.
Persistent iASD after PMVR does not affect 2-year outcomes; leaves open whether associated RV enlargement warrants selective closure.
Percutaneous mitral valve repair (PMVR) requires transseptal puncture and results in iatrogenic atrial septal defect (iASD). The impact of persistent iASD was previously investigated. However, data were diverse and inconclusive. 53 patients who underwent MITRACLIP were retrospectively included. Based on the presence of iASD in transesophageal echocardiography (TEE) after 6 months, patients were divided in two groups (iASD group vs. non-iASD group). Impact of iASD on outcome at 6 months and at two years was evaluated. Persistent iASD was detected in 62% of patients. Independent predictors for persistent iASD were female gender and reduced left ventricular ejection fraction. At 6-month follow-up, there was no difference in reduction of NYHA class (ΔNYHA = 1.3 ± 1 in iASD group vs. 0.9 ± 1 in non-iASD group, p = 0.171). There was a significant difference in right ventricular end diastolic diameter (RVEDd) (42 ± 8 mm in iASD-group vs. 39 ± 4 mm in non-iASD group, p = 0.047). However, right ventricular systolic function (TAPSE) (14 ± 7 mm in iASD group vs. 16 ± 8 mm in non-iASD group, p = 0.176) and right ventricular systolic pressure (RVSP) (40 ± 12 mmHg in iASD group vs. 35 ± 10 mmHg in non-iASD group, p = 0.136) were still comparable between both groups. At 2 years follow-up, there was no significant difference regarding rate of rehospitalization (24% vs 15%, p = 0.425) or mortality (12% vs 10%, p = 0.941) between both groups. Incidence of persistent iASD after MITRACLIP is markedly high. Despite the increase in right ventricular diameter in patients with persistent iASD, these patients were not clinically compromised compared to patients without persistent iASD.
No takes yet. Share an insight, caveat, or question.
Alachkar et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: